Accelerating the Shift to Downside Risk in Medicare Accountable Care Organizations: Effects on Clinical Quality and Costs among Older Patients

医疗保险责任医疗组织加速转向下行风险:对老年患者临床质量和成本的影响

基本信息

  • 批准号:
    10862329
  • 负责人:
  • 金额:
    $ 32.53万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-30 至 2025-04-30
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Older patients receive fragmented healthcare that is of variable quality and cost. To address this problem, the Centers for Medicare & Medicaid Services (CMS) developed accountable care organizations (ACOs). ACOs create incentives for providers to work together, while being mindful of their spending. Evaluations of the Medicare Shared Savings Program (MSSP)—CMS’s largest ACO initiative—show that participating organizations have improved care quality for older patients. Nonetheless, their costs remain high because they do not have enough “skin in the game.” The majority of ACOs have contracts in which they share a small percentage of the savings with Medicare when they reduce their annual costs below a benchmark but are not penalized if they fall short (i.e., they have no downside risk). Without the financial threat of downside risk, ACOs have less reason to innovate and increase efficiency. Thus, CMS announced “Pathways to Success” in December 2018, requiring current MSSP ACOs to shift to downside risk in as little as one year. However, shifting so quickly may be detrimental. The MSSP is voluntary, and many ACOs that have engaged in meaningful care redesign may not be ready to take on the possibility of having to repay CMS millions and leave the program instead. Indeed, 40% of ACOs facing contract renewal this July dropped out. Without the potential for shared savings, exiting ACOs may divest their data systems and coordination capabilities needed for population health management, which are costly to maintain. In turn, the ACOs’ patients may suffer lower care quality and higher costs. The decision to stay in the MSSP may have unintended consequences, too. ACOs may pursue cost-containment strategies like favorable patient selection. They may also limit their focus to CMS-required metrics (at the expense of other clinically important ones). These moves would hurt older patients who stand to gain the most from ACOs. In this context, we propose a combined qualitative and quantitative study with three Specific Aims. 1) To examine decisions around MSSP participation and the impact that these decisions have on an organization’s approach to care delivery after launch of Pathways to Success. Using administrative data, we will purposefully sample 12 ACOs without downside risk that faced contract renewal in 2019—six that renewed and six that did not. We will conduct semi-structured phone interviews with key stakeholders to better understand what factors influenced their participation decision and how their decision is affecting their efforts to improve care coordination and population health. 2) To assess the effects of MSSP exit on clinical quality and costs among older patients. We will analyze national Medicare claims (2008 to 2022) and identify MSSP-aligned fee-for-service beneficiaries. Among these beneficiaries, we will then measure their healthcare quality and costs (based on CMS-required outcome and process metrics and total price-standardized Medicare spending) before and after launch of Pathways to Success. 3) To evaluate for unintended consequences on older patients from continued participation. For ACOs identified in Aim 2 that remain in the MSSP, we will evaluate whether they take part in favorable patient selection. We will also measure their organizational performance against CMS-required and non- required outcome and process metrics before and after launch of Pathways to Success. Impact. Findings from our study will provide policymakers with actionable insights as they incorporate downside risk into advanced payment models and serve to inform ACO stakeholders who are considering organizational next steps.
项目概要 老年患者接受的医疗保健质量和成本参差不齐。 医疗保险和医疗补助服务中心 (CMS) 建立了责任医疗组织 (ACO)。 为供应商合作创造激励,同时关注他们的支出评估。 医疗保险共享储蓄计划 (MSSP)——CMS 最大的 ACO 计划——表明参与 尽管这些组织提高了老年患者的护理质量,但其成本仍然很高。 没有足够的“利益参与”。大多数 ACO 所签订的合同中,他们共享一小部分份额。 当他们将年度成本降低到基准以下但未达到基准时,医疗保险节省的百分比 如果他们没有达到目标(即没有下行风险),就会受到惩罚, ACO 没有太多理由进行创新和提高效率,因此 CMS 在 2017 年宣布了“成功之路”。 2018 年 12 月,要求当前的 MSSP ACO 在短短一年内转向下行风险。 如此迅速的转变可能会让人感到苦恼 MSSP 是自愿的,许多 ACO 都参与其中。 有意义的重新设计可能还没有准备好承担必须偿还 CMS 数百万美元的可能性,并且 事实上,今年 7 月面临续签合同的 ACO 中有 40% 退出了该计划。 共享节省的潜力,现有的 ACO 可能会剥离其所需的数据系统和协调能力 人口健康管理的维护成本高昂,反过来,ACO 的患者遭受的痛苦可能会更低。 留在 MSSP 的决定也可能会产生意想不到的后果。 ACO 可能会追求成本控制策略,例如有利的患者选择,他们也可能会限制他们的关注重点。 CMS 所需的指标(以牺牲其他临床重要指标为代价)。 在这种情况下,我们提出了一种综合的定性和可从 ACO 中获益的患者。 1) 检查有关 MSSP 参与的决策以及 这些决策对组织启动后提供护理服务的方法产生的影响 成功之路。使用管理数据,我们将有目的地对 12 个 ACO 进行抽样,而不会产生下行风险。 2019 年面临续签合同的企业——其中 6 家已续签,6 家未续签。我们将进行半结构化。 与主要利益相关者进行电话访谈,以更好地了解哪些因素影响了他们的参与决策 以及他们的决定如何影响他们改善护理协调和人口健康的努力。 我们将分析评估 MSSP 退出对老年患者临床质量和成本的影响。 国家医疗保险索赔(2008 年至 2022 年)并确定与 MSSP 一致的按服务收费受益人。 然后,我们将衡量他们的医疗保健质量和成本(基于 CMS 要求的结果和 流程指标和总价格标准化医疗保险支出)在推出 Pathways 之前和之后 3) 评估持续参与对老年患者的意外后果。 对于目标 2 中确定的仍保留在 MSSP 中的 ACO,我们将评估它们是否参与有利的 我们还将根据 CMS 要求和非 CMS 来衡量他们的组织绩效。 影响力调查结果发布之前和之后所需的结果和流程指标。 我们的研究将为政策制定者提供可行的见解,因为他们将下行风险纳入先进的 支付模型,并用于告知正在考虑组织后续步骤的 ACO 利益相关者。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

BRENT K. HOLLENBECK其他文献

BRENT K. HOLLENBECK的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('BRENT K. HOLLENBECK', 18)}}的其他基金

Physician dispensing of oral specialty drugs for advanced prostate cancer and its implications for patients
医生对晚期前列腺癌口服专科药物的配药及其对患者的影响
  • 批准号:
    10560826
  • 财政年份:
    2023
  • 资助金额:
    $ 32.53万
  • 项目类别:
Physician dispensing of oral specialty drugs for advanced prostate cancer and its implications for patients
医生对晚期前列腺癌口服专科药物的配药及其对患者的影响
  • 批准号:
    10862259
  • 财政年份:
    2023
  • 资助金额:
    $ 32.53万
  • 项目类别:
Aligning financial incentives to promote rational use of active surveillance for prostate cancer
调整财政激励措施以促进前列腺癌主动监测的合理使用
  • 批准号:
    10416477
  • 财政年份:
    2022
  • 资助金额:
    $ 32.53万
  • 项目类别:
Aligning financial incentives to promote rational use of active surveillance for prostate cancer
调整财政激励措施以促进前列腺癌主动监测的合理使用
  • 批准号:
    10592422
  • 财政年份:
    2022
  • 资助金额:
    $ 32.53万
  • 项目类别:
Accelerating the Shift to Downside Risk in Medicare Accountable Care Organizations: Effects on Clinical Quality and Costs among Older Patients
医疗保险责任医疗组织加速转向下行风险:对老年患者临床质量和成本的影响
  • 批准号:
    10625489
  • 财政年份:
    2020
  • 资助金额:
    $ 32.53万
  • 项目类别:
Accelerating the Shift to Downside Risk in Medicare Accountable Care Organizations: Effects on Clinical Quality and Costs among Older Patients
医疗保险责任医疗组织加速转向下行风险:对老年患者临床质量和成本的影响
  • 批准号:
    10432116
  • 财政年份:
    2020
  • 资助金额:
    $ 32.53万
  • 项目类别:
Impact of urologist practice organization and health policy on prostate cancer treatment, overtreatment and spending
泌尿科医生执业组织和卫生政策对前列腺癌治疗、过度治疗和支出的影响
  • 批准号:
    9750134
  • 财政年份:
    2017
  • 资助金额:
    $ 32.53万
  • 项目类别:
Impact of urologist practice organization and health policy on prostate cancer treatment, overtreatment and spending
泌尿科医生执业组织和卫生政策对前列腺癌治疗、过度治疗和支出的影响
  • 批准号:
    10224611
  • 财政年份:
    2017
  • 资助金额:
    $ 32.53万
  • 项目类别:
Accountable care organizations and the diffusion of new surgical procedures
负责任的护理组织和新外科手术的传播
  • 批准号:
    9067196
  • 财政年份:
    2015
  • 资助金额:
    $ 32.53万
  • 项目类别:
Accountable care organizations and the diffusion of new surgical procedures
负责任的护理组织和新外科手术的传播
  • 批准号:
    9522804
  • 财政年份:
    2015
  • 资助金额:
    $ 32.53万
  • 项目类别:

相似国自然基金

问责制度何以影响地方政府绩效——目标责任制情境下的“问责悖论”研究
  • 批准号:
    71103140
  • 批准年份:
    2011
  • 资助金额:
    21.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Privacy-Aware Federated Learning for Breast Cancer Risk Assessment
用于乳腺癌风险评估的隐私意识联合学习
  • 批准号:
    10742425
  • 财政年份:
    2023
  • 资助金额:
    $ 32.53万
  • 项目类别:
Global proteomics mass spectrometry data sharing infrastructure
全球蛋白质组质谱数据共享基础设施
  • 批准号:
    10556184
  • 财政年份:
    2023
  • 资助金额:
    $ 32.53万
  • 项目类别:
VoiceLove: An App-Based COMmunication Tool Designed to Address DeliriUm and Improve Family ENgagement and PatIent/Family SatisfaCtion in CriticAlly Ill PaTiEnts (COMMUNICATE)
VoiceLove:一种基于应用程序的通信工具,旨在解决危重患者的谵妄问题并提高家庭参与度和患者/家属满意度(沟通)
  • 批准号:
    10602709
  • 财政年份:
    2023
  • 资助金额:
    $ 32.53万
  • 项目类别:
Privacy-Preserving Connectivity for Rare-Disease Patients
罕见疾病患者的隐私保护连接
  • 批准号:
    10774186
  • 财政年份:
    2023
  • 资助金额:
    $ 32.53万
  • 项目类别:
Environmental and Sanitation Improvements with mHealth
通过移动医疗改善环境和卫生
  • 批准号:
    10741398
  • 财政年份:
    2023
  • 资助金额:
    $ 32.53万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了